Loading clinical trials...
Loading clinical trials...
Phase 2 Proof of Concept Study of Nivolumab and Ipilimumab in Children and Young Adults With Relapsed or Refractory INI1-negative Cancers
Conditions
Interventions
Nivolumab
Ipilimumab
Locations
8
United States
UCSF Benioff Children's Hospital
San Francisco, California, United States
Children's Healthcare of Atlanta-Egleston
Atlanta, Georgia, United States
Children's Healthcare of Atlanta-Scottish Rite
Atlanta, Georgia, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Boston Children's Hospital
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Start Date
August 14, 2020
Primary Completion Date
July 17, 2025
Completion Date
June 1, 2026
Last Updated
December 17, 2025
NCT07148050
NCT03099681
NCT06277154
NCT05407441
NCT03793166
NCT02114229
Lead Sponsor
Dana-Farber Cancer Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions